AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9691162 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of glucose intake (n = 11)
Number of subjects: 56
Study 9691162 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (n = 12)
Number of subjects: 56
Study 9691162 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 56
Study 7892363 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (exercise)
Number of subjects: 0
Study 7892363 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive exercise
Number of subjects: 0
Study 7892363 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive athletics involvement
Number of subjects: 0
Study 7892363 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise pre-dating dieting
Number of subjects: 0
Study 7892363 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity levels
Number of subjects: 0
Study 3360972 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg three times daily)
Number of subjects: 0
Study 3360972 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (1 mg orally)
Number of subjects: 0
Study 3360972 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (2 mg IV)
Number of subjects: 0
Study 29621098 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulation (VRS)
Number of subjects: 46
Study 29621098 — intervention group
Group type: COMPARATOR
Intervention: High-Fidelity Mannequin (group M)
Number of subjects: 46
Study 29621098 — intervention group
Group type: COMPARATOR
Intervention: Comparison of procedure time
Number of subjects: 46
Study 29621098 — intervention group
Group type: COMPARATOR
Intervention: Comparison of global rating scale scores
Number of subjects: 46
Study 28103915 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health volunteers (CHVs) providing health education, oral rehydration solutions, and zinc tablets for diarrhea, and diagnosing malaria.
Number of subjects: 0
Study 28103915 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no intervention during the first phase.
Number of subjects: 0
Study 26581144 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (topotecan) for 42 weeks, with local therapy of 50.4 Gy radiation therapy with or without delayed primary excision starting at week 12 for group III patients.
Number of subjects: 423
Study 26581144 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapy with 36-41.4 Gy radiation therapy for group I/II alveolar RMS patients.
Number of subjects: 423
Study 26581144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors ≥5 cm
Number of subjects: 423
Study 26581144 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal (RP) tumors
Number of subjects: 423
Study 23219491 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CBM-I training
Number of subjects: 28
Study 23219491 — intervention group
Group type: COMPARATOR
Intervention: Neutral CBM-I training
Number of subjects: 28
Study 21338720 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin dressing once daily
Number of subjects: 104
Study 21338720 — intervention group
Group type: COMPARATOR
Intervention: Normal saline dressing
Number of subjects: 104
Study 18451347 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA group (n=8841)
Number of subjects: 18145
Study 18451347 — intervention group
Group type: COMPARATOR
Intervention: no EPA group (n=8862)
Number of subjects: 18145
Study 18451347 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA group (n=485)
Number of subjects: 18145
Study 18451347 — intervention group
Group type: COMPARATOR
Intervention: no EPA group (n=457)
Number of subjects: 18145
Study 16750451 — intervention group
Group type: EXPERIMENTAL
Intervention: GAL-ER
Number of subjects: 965
Study 16750451 — intervention group
Group type: COMPARATOR
Intervention: GAL-IR
Number of subjects: 965
Study 16750451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 965
Study 15645861 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 7.5% sodium hexametaphosphate
Number of subjects: 0
Study 15645861 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 0
Study 11336940 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 60
Study 11336940 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone 0.12% twice daily
Number of subjects: 60
Study 11336940 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Latanoprost vs Unoprostone
Number of subjects: 60
Study 11336940 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 60
Study 9217619 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute office-staff administered screen for malnutrition/weight loss, visual impairment, hearing loss, cognitive impairment, urinary incontinence, depression, physical limitations, and reduced leg mobility.
Number of subjects: 261
Study 9217619 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute office-staff administered screen
Number of subjects: 261
Study 8429694 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (3)
Number of subjects: 60
Study 8429694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1)
Number of subjects: 60
Study 8429694 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 60
Study 3542916 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule (5 fractions per week of 180 to 200 cGy per day, total dose of 6600‐7380 cGy)
Number of subjects: 187
Study 3542916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation regimen (two fractions of 120 cGy per day, total of 6000 cGy)
Number of subjects: 187
Study 3542916 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule
Number of subjects: 187
Study 3542916 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation schedule
Number of subjects: 187
Study 30517236 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure levels in schoolchildren
Number of subjects: 1082
Study 30517236 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic and diastolic blood pressure analysis
Number of subjects: 1082
Study 30517236 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth measurements
Number of subjects: 1082
Study 30517236 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of pre-hypertension and arterial hypertension
Number of subjects: 1082
Study 26223834 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted distal gastrectomy (LADG)
Number of subjects: 63
Study 26223834 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 63
Study 24715213 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) followed by D2 gastrectomy
Number of subjects: 69
Study 23429740 — intervention group
Group type: EXPERIMENTAL
Intervention: NUCAI (nurse-led psychosocial intervention), consisting of six bimonthly 45-minute counseling sessions, aimed at managing physical, psychological, and social consequences of HNC and its treatment.
Number of subjects: 205
Study 23429740 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 102)
Number of subjects: 205
Study 20646356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract tablets
Number of subjects: 24
Study 20646356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18814223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary propranolol
Number of subjects: 400
Study 18814223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 16502132 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS (Positive Attitudes toward Learning in School)
Number of subjects: 90
Study 16502132 — intervention group
Group type: COMPARATOR
Intervention: Referral to neighborhood mental health clinic
Number of subjects: 90
Study 12740731 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar S710 mobile cycling powermeter
Number of subjects: 52
Study 10959510 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore External Valve Support (EVS)
Number of subjects: 30
Study 10959510 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (ligation or stripping)
Number of subjects: 30
Study 8793522 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (3 months before surgery)
Number of subjects: 247
Study 8793522 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 247
Study 1464343 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 1 mg
Number of subjects: 60
Study 1464343 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 2 mg
Number of subjects: 60
Study 1464343 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 3 mg
Number of subjects: 60
Study 1464343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 6369581 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional cefamandole
Number of subjects: 0
Study 6369581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefamandole
Number of subjects: 0
Study 6369581 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Control)
Number of subjects: 0
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of refined grains (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of red meat (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of potatoes (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of alcoholic beverages (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of processed meat (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of white bread (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of sweets (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of low-fat yogurt (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of low-fat milk (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of snacks, fast-foods and pre-prepared dishes (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of vegetables (1 serving/d)
Number of subjects: 7009
Study 31882021 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of nuts (1 serving/d)
Number of subjects: 7009
Study 28940962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 15 L/min
Number of subjects: 48
Study 28940962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 30 L/min
Number of subjects: 48
Study 28940962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow therapy at 45 L/min
Number of subjects: 48
Study 28940962 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 48
Study 27221555 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI) long-term therapy
Number of subjects: 0
Study 24337877 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive hydrotransmissive electrical stimulation (15) of the ear
Number of subjects: 120
Study 24337877 — intervention group
Group type: COMPARATOR
Intervention: Placebo electrical stimulation
Number of subjects: 120
Study 22317655 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise reminder software program (used for 10 weeks)
Number of subjects: 39
Study 22317655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 20534752 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (1-hour ergometer cycling at 65% maximal oxygen uptake)
Number of subjects: 8
Study 20534752 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (72 hours)
Number of subjects: 8
Study 17993008 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenwu gelatin capsule (5 capsules, 3 times a day for 3 months)
Number of subjects: 166
Study 17993008 — intervention group
Group type: COMPARATOR
Intervention: Aniracetam (2 capsules) with 3 placebo capsules (3 times a day for 3 months)
Number of subjects: 166
Study 16118755 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior mini-incision approach for THA
Number of subjects: 76
Study 12106834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 241
Study 12106834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 10413761 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC (heparin-coated circuits)
Number of subjects: 60
Study 10413761 — intervention group
Group type: COMPARATOR
Intervention: NHCC (uncoated circuits)
Number of subjects: 60
Study 7675881 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete caffeine deprivation (100% of daily caffeine intake)
Number of subjects: 9
Study 7675881 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial caffeine deprivation (50% of daily caffeine intake)
Number of subjects: 9
Study 7675881 — intervention group
Group type: COMPARATOR
Intervention: No caffeine deprivation (0% of daily caffeine intake)
Number of subjects: 9
Study 2126794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 24
Study 2126794 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 24
Study 6110953 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS radiation prophylaxis
Number of subjects: 3161
Study 6110953 — intervention group
Group type: COMPARATOR
Intervention: 3 years of maintenance treatment
Number of subjects: 3161
Study 6110953 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of maintenance treatment
Number of subjects: 3161
Study 31514107 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle radiomic features
Number of subjects: 116
Study 31514107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for muscle loss using 193 features
Number of subjects: 116
Study 31514107 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in intensity and texture radiomic features over time
Number of subjects: 116
Study 29872264 — intervention group
Group type: EXPERIMENTAL
Intervention: levodropropizine CR 90 mg two times in the fed state (TF)
Number of subjects: 47
Study 29872264 — intervention group
Group type: EXPERIMENTAL
Intervention: levodropropizine CR 90 mg two times in the fasted state (T)
Number of subjects: 47
Study 29872264 — intervention group
Group type: COMPARATOR
Intervention: levodropropizine IR 60 mg three times in the fasted state (R)
Number of subjects: 47
Study 26185283 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Glycemic Index (LGI) diet (n = 72; target GI ∼50)
Number of subjects: 139
Study 26185283 — intervention group
Group type: COMPARATOR
Intervention: High-Fiber (HF) diet (n = 67; target GI ∼60)
Number of subjects: 139
Study 25175696 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP concentration change during admission
Number of subjects: 309
Study 25175696 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP concentration change from discharge to 1 month after discharge
Number of subjects: 309
Study 25175696 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute NT-proBNP concentration at 1 month after discharge
Number of subjects: 309
Study 21818642 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g ginger
Number of subjects: 576
Study 21818642 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g ginger
Number of subjects: 576
Study 21818642 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g ginger
Number of subjects: 576
Study 21818642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 19336855 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular intensifying screens
Number of subjects: 45
Study 19336855 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium intensifying screens
Number of subjects: 45
Study 19336855 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital radiography
Number of subjects: 45
Study 17767803 — intervention group
Group type: EXPERIMENTAL
Intervention: Inert cellulose powder
Number of subjects: 15
Study 17767803 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose powder)
Number of subjects: 15
Study 16946178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 570
Study 16946178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 12103457 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT without atropine
Number of subjects: 29
Study 12103457 — intervention group
Group type: COMPARATOR
Intervention: ECT with atropine
Number of subjects: 29
Study 12103457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative poststimulus RPP
Number of subjects: 29
Study 9527731 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 9527731 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 60
Study 7892822 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 392
Study 7892822 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 392
Study 7892822 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 392
Study 7892822 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 392
Study 2649632 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol at 80 mg
Number of subjects: 32
Study 2649632 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol at 50 mg
Number of subjects: 32
Study 2649632 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol at 100 mg
Number of subjects: 32
Study 2649632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2649632 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32
Study 2649632 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal clearance and urinary excretion
Number of subjects: 32
Study 788891 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + methyl CCNU
Number of subjects: 146
Study 788891 — intervention group
Group type: COMPARATOR
Intervention: Methyl CCNU alone
Number of subjects: 146
Study 788891 — intervention group
Group type: COMPARATOR
Intervention: Methyl CCNU with cyclophosphamide induction
Number of subjects: 146
Study 788891 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU + methyl CCNU with cyclophosphamide induction
Number of subjects: 146
Study 31003666 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage using sweet almond oil
Number of subjects: 150
Study 31003666 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage using lavender and sweet almond oil
Number of subjects: 150
Study 31003666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 28760007 — intervention group
Group type: EXPERIMENTAL
Intervention: Double fortified salt (DFS)
Number of subjects: 245
Study 28760007 — intervention group
Group type: COMPARATOR
Intervention: Salt fortified with iodine (control)
Number of subjects: 245
Study 26200405 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine + tramadol 50 mg
Number of subjects: 80
Study 26200405 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine + fentanyl 150 mcg
Number of subjects: 80
Study 26200405 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 2.5 mg/ml
Number of subjects: 80
Study 26200405 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 80
Study 22390703 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward-informed condition
Number of subjects: 84
Study 22390703 — intervention group
Group type: COMPARATOR
Intervention: Reward-uninformed condition
Number of subjects: 84
Study 21680932 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention providing diabetes self-management education and regular home visits for 6 months
Number of subjects: 164
Study 21680932 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed control)
Number of subjects: 164
Study 21680932 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 164
Study 19073386 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 40
Study 19073386 — intervention group
Group type: COMPARATOR
Intervention: Flammazine (Control)
Number of subjects: 40
Study 15946711 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-side vertically arranged stimuli
Number of subjects: 0
Study 15946711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilesional 'good' side stimuli
Number of subjects: 0
Study 14514648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1168
Study 14514648 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1168
Study 11451211 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 0
Study 9625405 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus partial ileal bypass intervention
Number of subjects: 838
Study 9625405 — intervention group
Group type: COMPARATOR
Intervention: Diet control
Number of subjects: 838
Study 7749401 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (dental history variable)
Number of subjects: 310
Study 3175579 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1 g suppositories)
Number of subjects: 187
Study 3175579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole (500 mg iv or 500 mg suppositories)
Number of subjects: 187
Study 1061225 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic bench press at 1.5 sec speed
Number of subjects: 11